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OBJECTIVES The aim of this study was to evaluate the association between valvular heart disease (VHD)
and maternal and fetal outcome in a relatively large group of patients by a comparison to a
well-matched control group.
BACKGROUND Available information regarding outcome of pregnancy in women with VHD is limited to
either anecdotal reports or small series of patients without an appropriate control. A better
understanding of the effects of valvular abnormalities on pregnancy outcome is of value for
risk assessment and the design of a therapeutic plan.
METHODS A retrospective evaluation was made of 66 pregnancies in 64 women with VHD cared for at
a tertiary-care center with a high-risk obstetrics/cardiology clinic and 66 individually selected
normal pregnant women matched in age, ethnicity, obstetrical and medical history, time of
initial prenatal care, and year of pregnancy.
RESULTS Women with VHD had a significantly higher incidence of congestive heart failure (38% vs.
0%; p , 0.00001), arrhythmias (15% vs. 0%, p 5 0.002), initiation or increase of cardiac
medications (41% vs. 2%, p , 0.0001), and hospitalizations (35% vs. 2%, p , 0.0001).
Mortality, however, occurred in only one patient (2% vs. 0%, p 5 NS) with aortic stenosis
(AS) and coarctation. Moreover, VHD also had an effect on fetal outcome, resulting in an
increased preterm delivery (23% vs. 6%, p 5 0.03), intrauterine growth retardation (21% vs.
0%, p , 0.0001), and a reduced birth weight (2897 6 838 g vs. 3366 6 515 g, p 5 0.0003).
Increased maternal morbidity and unfavorable fetal outcome were seen mostly in patients with
moderate and severe mitral stenosis (MS) and AS.
CONCLUSIONS Pregnancy in women with MS and AS is associated with marked increase in maternal
morbidity and unfavorable effect on fetal outcome, which are related to severity of disease.
Despite high maternal morbidity, mortality is rare. (J Am Coll Cardiol 2001;37:893–9)
© 2001 by the American College of Cardiology
Management of pregnancy in patients with valvular heart
disease (VHD) continues to pose a challenge to the clini-
cian. Although the risks in such patients have been recog-
nized (1), they have not been well defined because available
information is based mostly on anecdotal reports or small
series of patients without an appropriate control population
(2–4).
The present study was, therefore, designed to evaluate the
effect on VHD on maternal and fetal outcome in a relatively
large group of patients cared for in a single institution by a
comparison with a well-matched group of normal pregnant
women.
METHODS
The study was designed as a retrospective evaluation of
pregnancy outcome in patients with VHD in comparison to
that of normal controls. All cases were followed during
pregnancy, labor, and delivery at the Los Angeles County/
University of Southern California Medical Center, a
tertiary-care facility with a high-risk obstetrics/cardiology
clinic, and the study protocol was approved by the institu-
tional review board of the LAC/USC Medical Center.
Exclusions included: 1) incomplete records, 2) prosthetic
heart valves, and 3) therapeutic abortion for noncardiac
reasons. The study population was divided into three major
subgroups based on their predominant valvular disease (i.e.,
mitral, aortic, and pulmonic valve). Mitral stenosis (MS)
and aortic stenosis (AS) were classified according to calcu-
lated valve area established by either cardiac catheterization
or echocardiography as mild for valve area .1.5 cm2,
moderate 1.0 to 1.5 cm2, and severe ,1.0 cm2 (5). Four
patients with predominant mitral regurgitation (MR) were
included in the mild group. For each studied patient, a
control case was selected individually from delivery records
at the same Medical Center to match the patient in age,
ethnicity, obstetrical and medical history, time of initial
prenatal care, and year of pregnancy. Separate control cases
were used to match two different pregnancies in two of the
patients.
Data analysis. The data were analyzed to evaluate maternal
as well as fetal outcome. Criteria for maternal outcome
included: 1) change in New York Heart Association
(NYHA) functional class; 2) new onset of congestive heart
failure (CHF); 3) hospitalizations not related to labor and
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delivery; 4) new onset or exacerbation of arrhythmias; 5)
need either to initiate or enhance dose of cardiac medica-
tions; and 6) mode of delivery. Criteria for fetal outcome
included: 1) preterm labor, 2) stillbirth, and 3) birth weight.
Comparisons of baseline characteristics and the criteria
evaluated for maternal and fetal outcome between patients
with valvular disease and controls were performed using the
two-tailed Fisher exact test. Patients’ ages, duration of
pregnancy and neonatal birth weights were compared with
the use of a nonpaired t test. All values were presented as
mean 6 SD. Statistical significance was accepted at the 95%
confidence level (p , 0.05).
RESULTS
Patient population. Sixty-six pregnancies in 64 patients
met the inclusion criteria and were included in this study.
There were 46 pregnancies in 44 patients with predominant
mitral valve disease. Nineteen of these pregnancies occurred
in patients with mild, 18 in moderate and 9 with severe MS.
Additional valvular abnormalities included MR in 12 pa-
tients, MR and mild AS in 1 patient, aortic regurgitation
(AR) in 2 patients and combined AR and mild AS in 1
patient. Twelve of the patients had predominant AS, which
was qualified as severe in three, moderate in six and mild in
three patients. Two patients had, in addition, AR, and one
patient had moderate MS. Eight patients had pulmonic
stenosis (PS), with a mean peak pressure gradient across the
pulmonic valve of 59 6 35 mm Hg (25 to 110 mm Hg).
Table 1 lists demographic information and baseline
characteristics of the studied cases and their controls. There
was a close match between the two groups in age, ethnicity,
medical history, prenatal care, and the year of care. Obstet-
rical history was also identical except for higher number of
previous abortions in patients with VHD (32 vs. 18, p 5
0.017).
All Patients
Maternal outcome. Thirty-six (55%) of the VHD patients
were in the NYHA functional class I; 28 (42%) were in class
II, and 2 (3%) in class III on presentation. Heart disease was
previously known in 25 class I patients, 16 class II patients,
and 1 class III patient. Forty patients (62%) showed a
deterioration of at least one functional class during preg-
nancy (Figs. 1 and 2), which occurred during the first
trimester in 8 patients, second trimester in 26 patients and
third trimester in 6 patients. Differences in maternal out-
come between patients and controls are shown in Table 2.
Patients with VHD demonstrated a significantly higher
incidence of CHF, arrhythmias and hospitalizations during
pregnancy. Thirty-four patients (52%) required cardiac
medications during their index pregnancy, which included:
diuretics, 27 patients; beta-blocking agents, 22 patients;
calcium channel blockers, 13 patients; digoxin, 9 patients;
potassium chloride, 7 patients; heparin, 4 patients; hydra-
lazine, 1 patient; and aspirin, 1 patient. In 27 of these
patients, therapy was either initiated or increased during
pregnancy (first trimester, 8 patients; second trimester, 18
patients; third trimester, 1 patient).
In comparison, one patient in the control group was
started on warfarin during pregnancy owing to deep-vein
thrombosis. Mortality occurred in one valvular case and in
none of the control cases (p 5 NS).
Mode of delivery. Mode of delivery was vaginal in 61 of 66
(92%) cases with VHD and in 58 (87%) of controls (p 5
NS). Spontaneous vaginal delivery was reported in all 58
control cases but in only 38 (58%) of the patients (p 5 NS),
whereas the remaining patients had either a forceps or
vacuum delivery. Cesarean section was performed in eight
control cases (all for obstetrical reasons) and in five VHD
patients—two for cardiac reasons, including heart failure in
one patient and acute ischemic syndrome in another.
Postdelivery complications. Pulmonary edema developed
in three patients with MS (1 severe and 2 moderate) and in
Abbreviations and Acronyms
AR 5 aortic regurgitation
AS 5 aortic stenosis
CHF 5 congestive heart failure
IUGR 5 intrauterine growth retardation
MR 5 mitral regurgitation
MS 5 mitral stenosis
NYHA 5 New York Heart Association
PS 5 pulmonic stenosis
VHD 5 valvular heart disease
Table 1. Baseline Characteristics
Characteristics Patients Controls
p
Value
Number of pregnancies 66 66 1
Age (yrs) 16–42 (29 6 7) 17–42 (29 6 7) 1
Ethnicity
Hispanic 63 63 1
Filipino 2 2 1
Black 1 1 1
Obstetric history
Primigravida 16 15 1
Multiparous 48 49 1
Abortions 32 18 0.017
Medical history
Pregnancy-induced
hypertension
5 4 1
Pyelonephritis 2 3 1
Chronic hypertension 2 2 1
Antiphospholipid syndrome 2 0 0.49
Hypercholesterolemia 2 0 0.49
Coronary artery disease 2 0 0.49
Prenatal care
First trimester 24 24 1
Second trimester 34 34 1
Third trimester 6 6 1
Year of delivery
1979–1984 3 3 1
1985–1989 16 16 1
1990–1994 28 28 1
1995–1998 19 19 1
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two patients with moderate and severe AS post-delivery,
and pneumonia developed in one patient with severe MS.
Fetal outcome. Information on fetal outcome is shown in
Table 3. Stillbirth was reported in 3% of patients with VHD
and in none of the controls (p 5 NS). Three percent of the
patients had spontaneous abortions, and 5% had therapeutic
abortions. Because information related to the control group
was obtained retrospectively from delivery records, no data
could be obtained regarding incidence of abortions in this
population. A statistically significant difference occurred in
the duration of pregnancy (35 6 7 vs. 39 6 2 weeks, p ,
0.0002), in the incidence of premature deliveries, and in the
incidence of intrauterine growth retardation (IUGR). In
addition, birth weight was substantially lower in the patients
when compared to controls. Six pregnancies lasted fewer
than 32 weeks, and birth weight was # the 10th percentile
of the California Growth Curve in 13 cases with VHD and
none in the controls. The Apgar scores were ,8 at 1 min in
9 of 66 patients and in 1 of 66 of the controls and at 5 min
in 6 of 66 of patients and 0 of 66 of controls (p 5 0.588).
Subgroup Evaluation
Mitral stenosis. There were 46 pregnancies in 44 patients
with predominant MS. In 28 of these pregnancies, patients
were in the NYHA functional class I on their first visit and
18 were in class II (Fig. 1). Thirteen class I patients
advanced during pregnancy to class II, eight to class III and
two to class IV. Seven class II patients advanced to class III
and four to class IV. Both maternal and fetal outcomes were
comparable in patients with mild MS and their control. In
contrast, there was a significantly higher incidence of CHF,
arrhythmias, need to initiate or increase dose of cardiac
medications, and hospitalizations in patients with moderate
and severe MS compared to their controls (Table 2).
Despite high incidence of maternal morbidity, no mortality
was reported in this group of patients. The effect of
hemodynamically significant mitral valve disease on fetal
outcome (Table 3) was reflected by a markedly increased
rate of IUGR and lower birth weight. The incidence of
preterm birth was higher in patients with mitral valve
disease compared to controls; the difference, however, was
not statistically significant (p 5 0.2 for all MS patients and
p 5 0.09 for patients with moderate and severe MS).
Aortic stenosis. There were 12 pregnancies in 12 women
with predominant AS. In five of these pregnancies, patients
were in the NYHA functional class I on their first visit, five
were in class II and two were in class III. Two class I
patients advanced during pregnancy to class II, three class II
patients advanced to class III and two class III patients
advanced to class IV. There was a higher incidence of
maternal CHF, arrhythmias, need to initiate or increase
dose of cardiac medications, and hospitalizations in patients
Figure 1. Change in New York Heart Association (NYHA) functional
class between first visit and follow-up during pregnancy in patients with
predominant mitral valve disease. Circles, mild mitral stenosis; squares,
moderate mitral stenosis; diamonds, severe mitral stenosis. Open symbols,
NYHA functional class I on presentation; closed symbols, NYHA
functional class II on presentation.
Figure 2. Change in New York Heart Association (NYHA) functional
class between first visit and follow-up during pregnancy in patients with
predominant aortic and pulmonic valve disease. Circles, mild aortic
stenosis; squares, moderate aortic stenosis; diamonds, severe aortic steno-
sis, triangles, pulmonic stenosis. Open symbols, NYHA functional class I
on presentation; closed symbols, NYHA class II on presentation; dotted
diamonds, NYHA functional class III on presentation.
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with AS compared to their controls. Congestive heart
failure was reported in 44% of patients with moderate and
severe AS, arrhythmias in 25%, new medications in 33%,
and hospitalizations in 33% of patients. Because of the
limited number of patients, incidence of CHF was only
borderline statistically significant (p 5 0.06), and differences
in maternal morbidity between the two groups did not reach
statistical significance. Similar to maternal outcome, fetal
outcome also seemed to be affected by the presence of mod-
erate and severe aortic valve disease as suggested by a higher
incidence of preterm birth (44%), IUGR (22%), and lower
birth weight (2650 6 987 vs. 3391 6 412 g, p 5 0.002).
Pulmonic stenosis. Three of the eight patients with PS
were in the NYHA functional class I and five in class II on
Table 2. Maternal Outcome in Patients With Valvular Heart Disease and Their Controls
Valve
Severity
CHF Arrhythmias Medications Hospitalizations Mortality
PTS CTRL p PTS CTRL p PTS CTRL p PTS CTRL p PTS CTRL p
Mitral
Mild 11%
(2/19)
0%
(0/19)
0.5 0%
(2/19)
0%
(0/19)
1.0 5%
(1/19)
5%
(1/19)
1.0 11%
(2/19)
0%
(0/19)
0.5 0%
(0/19)
0%
(0/19)
1.0
Moderate 61%
(11/18)
0%
(0/18)
, 0.01 22%
(4/18)
0%
(0/18)
0.1 72%
(13/18)
0%
(0/18)
, 0.01 61%
(11/18)
0%
(0/18)
, 0.01 0%
(0/18)
0%
(0/18)
1.0
Severe 78%
(7/9)
0%
(0/9)
, 0.05 33%
(3/9)
0%
(0/9)
0.23 100%
(9/9)
0%
(0/9)
, 0.02 78%
(7/9)
11%
(1/9)
, 0.1 0%
(0/9)
0%
(0/9)
1.0
All 43%
(20/46)
0%
(0/46)
, 0.0001 20%
(9/46)
0%
(0/46)
, 0.0001 50%
(23/46)
2%
(1/46)
43%
(20/46)
2%
(1/46)
, 0.001 0%
(0/46)
0%
(0/46)
1.0
Aortic
Mild 33%
(1/3)
0%
(0/3)
1.0 0%
(0/3)
0%
(0/3)
1.0 33%
(1/3)
0%
(0/3)
1.0 0%
(0/3)
0%
(0/3)
1.0 0%
(0/3)
0%
(0/3)
1.0
Moderate 17%
(1/6)
0%
(0/6)
1.0 0%
(0/6)
0%
(0/6)
1.0 33%
(2/6)
0%
(0/6)
17%
(1/6)
0%
(0/6)
1.0 0%
(0/6)
0%
(0/6)
1.0
Severe 100%
(3/3)
0%
(0/3)
0.5 33%
(1/3)
0%
(0/3)
1.0 33%
(1/3)
0%
(0/3)
1.0 67%
(2/3)
0%
(0/3)
0.5 33%
(1/3)
0%
(0/3)
1.0
All 42%
(5/12)
0%
(0/12)
0.06 8%
(1/12)
0%
(0/12)
1.0 33%
(4/12)
0%
(0/12)
25%
(3/12)
0%
(0/12)
0.2 8%
(1/12)
0%
(0/12)
1.0
Pulmonic 0%
(0/8)
0%
(0/8)
1.0 0%
(0/8)
0%
(0/8)
1.0 0%
(0/8)
0%
(0/8)
1.0 0%
(0/8)
0%
(0/12)
1.0 0%
(0/8)
0%
(0/8)
1.0
All patients 38%
(25/66)
0%
(0/6)
, 0.0001 15%
(10/66)
0%
(0/66)
0.001 41%
(27/66)
2%
(1/66)
, 0.0001 35%
(23/66)
2%
(1/66)
, 0.0001 2%
(1/66)
0%
(0/66)
1.0
CTRL 5 controls; PTS 5 patients.
Table 3. Fetal Outcome in Patients With Valvular Heart Disease Versus Controls
Valve
Severity
Preterm Delivery IUGR Stillbirth Birth Weight (g)
PTS CTRL p PTS CTRL p PTS CTRL p PTS CTRL p
Mitral
Mild 5%
(1/19)
11%
(2/19)
1.0 16%
(3/19)
0%
(0/19)
0.6 0%
(0/19)
0%
(0/19)
1.0 3,135 6 419 3,288 6 531 0.3
Moderate 28%
(5/18)
6%
(1/18)
0.2 27%
(5/18)
0%
(0/18)
0.1 5%
(1/18)
0%
(0/18)
1.0 2,706 6 1,039 3,427 6 426 0.02
Severe 44%
(4/9)
11%
(1/9)
0.3 33%
(3/9)
0%
(0/9)
0.5 11%
(1/9)
0%
(0/9)
1.0 2,558 6 947 3,332 6 403 0.05
All 22%
(10/46)
9%
(4/46)
0.2 24%
(11/46)
0%
(0/46)
, 0.001 4%
(2/46)
0%
(0/46)
0.5 2,845 6 818 3,372 6 486 0.02
Aortic
Mild 0%
(0/3)
0%
(0/3)
1.0 33%
(1/3)
0%
(0/3)
1.0 0%
(0/3)
0%
(0/3)
1.0 3,227 6 843 3,083 6 878 0.85
Moderate 33%
(2/6)
0%
(0/6)
0.5 33%
(2/6)
0%
(0/6)
0.5 0%
(0/6)
0%
(0/6)
1.0 2,450 6 1,460 3,763 6 511 0.08
Severe 66%
(2/3)
0%
(0/3)
0.5 0%
(0/3)
0%
(0/3)
1.0 0%
(0/3)
0%
(0/3)
1.0 1,838 6 1,170 3,265 6 141 0.2
All
(4/12) (0/12)
0.1 25%
(3/12)
0%
(0/12)
0.2 0%
(0/12)
0%
(0/12)
1.0 2,752 6 1,017 3,385 6 694 0.09
Pulmonic 12%
(1/8)
0%
(0/8)
1.0 25%
(1/8)
0%
(0/8)
1.0 0%
(0/8)
0%
(0/8)
1.0 3,376 6 565 3,300 6 429 0.8
All patients 23%
(15/66)
6%
(4/66)
0.03 21%
(14/66)
0%
(1/66)
0.0001 3%
(2/66)
0%
(0/66)
0.5 2,897 6 838 3,365 6 515 , 0.001
CTRL 5 controls; IUGR 5 intrauterine growth retardation; PTS 5 patients.
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presentation. None of the patients showed a significant
deterioration during pregnancy (Fig. 2). In addition, there
were no hospitalizations, arrhythmias, or need to initiate
cardiac medications in this group during gestation (Table
2), and all pregnancies resulted in a live birth. One preterm
birth and one case of IUGR occurred compared to none in
the controls (Table 3). Differences between the groups,
however, were not statistically significant. Mean birth
weight was similar in the two groups.
DISCUSSION
The results of the present study demonstrate a significant
impact of VHD on both maternal and fetal outcome.
Maternal outcome. Women with VHD had a high rate of
clinical deterioration and a marked increase in morbid
events during pregnancy, including CHF, arrhythmias and
need to either initiate or increase cardiovascular drug ther-
apy or to hospitalize patients during pregnancy. An in-
creased incidence of CHF in patients with VHD is not
surprising owing to the marked hemodynamic changes
normally occurring during gestation (6). Increased hemody-
namic burden during gestation is also a possible mechanism
for new onset or worsening of existing arrhythmias observed
in this study in women with VHD. Increased incidence of
cardiac arrhythmias has also been described in healthy
women during pregnancy (7–11), and this may be related to
gestational hormonal effect and a possible increased sensi-
tivity to catecholamines during gestation (12). Such ar-
rhythmias, however, are uncommon, and they were not
reported in any of the women in the control group.
Fetal outcome. In addition to the effect on maternal
morbidity, the present study also demonstrated an effect of
VHD on fetal outcome. Pregnancy in our patients was
associated with an increased incidence of IUGR, preterm
deliveries, and lower birth weight, especially in cases with
moderate and severe stenosis of the mitral or aortic valve.
Hemodynamic compromise secondary to valvular stenosis
and the resulting decrease in uterine blood flow are probable
explanations for the high incidence of impaired intrauterine
fetal growth seen in this study of patients with VHD.
In addition, maternal arrhythmias have been shown to
cause fetal distress (10) and may be an additional mecha-
nism leading to compromised uterine blood flow and fetal
outcome. Although the fetal effect of cardiovascular drugs
used in many of the patients cannot be assessed, such
medications, including diuretics, digitalis, and beta-
adrenergic blocking agents, have been associated with im-
pairment of uterine blood flow or with increased incidence
of IUGR or prematurity (13–17). The increased incidence
of IUGR shown in this study suggests the need for
antepartum fetal surveillance and serial ultrasound determi-
nations of fetal growth in all cases of moderate and severe
aortic and mitral valve disease.
Relation to type and severity of VHD. Although sub-
group analysis of our findings may be limited owing to a
relative small number of patients in each subgroup, a clear
relationship can be found between the severity of MS and
AS and maternal as well as fetal outcome. Though the
overall incidence of complications was high in patients with
moderate and severe disease, the outcome of pregnancy in
most patients with mild MS and AS was comparable to that
of their normal controls.
Despite the relative severity of PS in our patients,
pregnancy was well tolerated and outcome was comparable
to that seen in their control patients. Although this finding
supports previously reported clinical experience (18–20), the
number of patients with PS in the present study was small
and the results cannot be conclusive.
Maternal mortality. Despite a high incidence of maternal
morbidity, mortality was limited to one patient (2%) with
severe AS combined with coarctation of the aorta. Further-
more, because mortality occurred in the postpartal period
(1), 10 days following a successful abdominal delivery and in
conjunction with surgery for aortic valve replacement, the
association between this patient’s death and pregnancy was
questionable. Our data, supported by other reports
(4,21,22), indicate, therefore, that with early diagnosis and
careful follow-up, mortality is rare in medically treated
patients with VHD at NYHA functional class I and II.
Valvular repair during pregnancy. Valvular repair, either
surgically or by percutaneous balloon valvuloplasty, is the
procedure of choice in symptomatic, nonpregnant patients
with VHD. Successful cardiovascular surgery has been
reported during pregnancy (23,24). The overall experience,
however, suggests a moderate increase in maternal risk and
an unpredictable risk to the fetus or neonate (24,25). The
use of percutaneous balloon valvuloplasty during pregnancy
has been reported in patients with both mitral and aortic
stenosis (26–31). A recent study by Ben Farhat et al. (27)
reported on forty-four pregnant patients who underwent
percutaneous balloon valvuloplasty of the mitral valve be-
tween 1990 and 1996 with a significant hemodynamic
benefit and a favorable pregnancy outcome. These data
compare favorably to our findings and may support the use
of percutaneous balloon valvuloplasty during pregnancy in
patients with moderate to severe MS. At the same time,
however, important valvuloplasty-related complications in-
cluding cardiac tamponade, systemic embolization, maternal
arrhythmias, initiation of uterine contractions, fetal distress
and fetal loss have been reported (27,30–32). These poten-
tial complications, in addition to fetal risk due to unavoid-
able ionizing radiation (33), indicate the need for additional
data and appropriate, controlled comparison with medical
therapy before widespread use of percutaneous balloon
valvuloplasty can be recommended during pregnancy.
Mode of delivery. The majority of patients with VHD as
well as their controls were delivered vaginally. Although a
high incidence of vaginal delivery in this study reflects
practice approach in our institution, these findings indicate
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that cesarean section, which is often performed as a pre-
ferred delivery method in patients with heart disease, should
be reserved for patients with obstetrical indications or
cardiac instability.
Postdelivery complications. Development of pulmonary
edema in five patients early postdelivery is most likely
related to increased venous return due to relief of inferior
caval compression (7). These findings suggest a rationale for
close hemodynamic monitoring during labor, delivery, and
the early postpartum period in patients with significant
vavlular stenosis.
Summary and clinical implications. The present study
demonstrates an important effect of VHD on both maternal
and fetal outcome of pregnancy. Increased maternal mor-
bidity was reflected by clinical deterioration in more than
half of the patients, high incidence of CHF and cardiac
arrhythmias, and the need either to initiate or enhance
cardiovascular drug therapy and to hospitalize many of the
patients during pregnancy. Maternal mortality was low and
occurred in only one patient with severe AS and coarctation
(,2%) after surgery. In addition, presence of maternal
VHD had an important effect on fetal outcome, leading to
increased incidence of IUGR, premature labor, and de-
creased birth weight. The effect of VHD on pregnancy
outcome was seen mostly in patients with moderate and
severe AS and MS, whereas only little or no effect was noted
in patients with mild degree of these conditions and in those
with PS.
Finally, the results of this study indicate the need for close
maternal follow-up and fetal surveillance in pregnant pa-
tients with moderate or severe AS and MS. Repair of
valvular stenosis in such patients should be performed prior
to pregnancy, if possible. Balloon valvuloplasty should be
considered during pregnancy in order to prevent maternal
and fetal complications. The possible benefits of this pro-
cedure, however, should be carefully weighed against its
potential risks during pregnancy.
APPENDIX
Abortion is the termination of pregnancy by any means
before the fetus is sufficiently developed to survive. In the
United States this definition is confined to the termination
of pregnancy before 20 weeks based on the date of the first
day of the last normal menses.
Preterm is defined as infants delivered prior to the
completion of 37 weeks (American College of Obstetricians
and Gynecologists, 1995).
Intrauterine growth retardation. This term is used synon-
ymously as small for gestational age (SGA) infants are those
whose weights are below the 10th percentile for their
gestational age. (Lubchenco LO, Hansman C, Dressler M,
Boyd E. Intrauterine growth as estimated from live-born
birth-weight data at 24 to 42 weeks of gestation. Pediatrics
1963;32:793.)
Stillbirth. None of the signs of life are present at or after birth.
(Williams Obstetrics. 20th ed. Appleton & Lange, 1997).
(F. Gary Cunningham, MD; Paul C. MacDonald, MD;
Norman F. Gand, MD; Kenneth J. Leveno, MD; Lary C.
Gilstrap III, MD; Gary D.V. Hankins, MD; Steven L.
Clark, MD, editors. Obstetrics in Broad Perspective, pp.
1–11)
Reprint requests and correspondence: Uri Elkayam, MD, USC
School of Medicine, Division of Cardiology, 2025 Zonal Ave, Los
Angeles, California 90033. E-mail: elkayam@hsc.usc.edu.
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